Stock analysts at StockNews.com began coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.
NanoViricides Stock Down 0.4 %
NYSE:NNVC opened at $2.22 on Friday. The firm has a market capitalization of $26.22 million, a price-to-earnings ratio of -2.71 and a beta of 0.70. The stock’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.24. NanoViricides has a twelve month low of $1.00 and a twelve month high of $2.35.
NanoViricides (NYSE:NNVC – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.16) earnings per share for the quarter.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
See Also
- Five stocks we like better than NanoViricides
- Trading Halts Explained
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- Insider Trades May Not Tell You What You Think
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
